Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMRC Horizon Two in High-Risk Newly Diagnosed Multiple Myeloma
NCT07053436Phase 2Recruiting
- Start
- Apr 2026
- Primary completion
- Oct 2035
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of linvoseltamab in multiple myeloma (MM). Started Apr 2026; status: recruiting.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07053436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053436.